abs315.txt	although	cancer	immunotherapy	based	on	immune	checkpoint	inhibitors	holds	greatpromise	toward	many	types	of	cancers		several	challenges	still	remain		associatedwith	low	objective	response	of	patient	rate	as	well	as	systemic	side	effects	here		a	combination	immunotherapy	strategy	is	developed	based	on	a	thermogellingreactive	oxygen	species	(ros)-responsive	polypeptide	gel	for	sustained	release	ofanti-programmed	cell	death-ligand	1	antibody	and	dextro-1-methyl	tryptophan	inhibitor	of	indoleamine-2	3-dioxygenase	with	leveraging	the	ros	level	in	thetumor	microenvironment		this	bioresponsive	gel	depot	can	effectively	reduce	thelocal	ros	level	and	facilitate	release	of	immunotherapeutics		which	leads	toenhanced	anti-melanoma	efficacy	in	vivo	
